|
1
|
Nilsson J, Vallbo C, Guo D, Golovleva I,
Hallberg B, Henriksson R and Hedman H: Cloning, characterization
and expression of human LIG1. Biochem Biophys Res Commun.
284:31–37. 2001. View Article : Google Scholar
|
|
2
|
Hedman H, Nilsson J, Guo D and Henriksson
R: Is LRIG1 a tumour suIs LRIG1 a tumour suppressor gene at
chromosome 3p14.3? Acta Oncol. 41:352–354. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Laederich MB, Funes-Duran M, Yen L,
Ingalla E, Wu X, Carraway KL III and Sweeney C: The leucine-rich
repeat protein LRIG1 Is a negative regulator of ErbB family
receptor tyrosine kinases. J Biol Chem. 279:47050–47056. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gur G, Rubin C, Katz M, Amit I, Citri A,
Nilsson J, Amariglio N, Henriksson R, Rechavi G, Hedman H, et al:
LRIG1 restricts growth factor signaling by enhancing receptor
ubiquitylation and degradation. EMBO J. 23:3270–3281. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang Y, Poulin EJ and Coffey RJ: LRIG1 is
a triple threat: ERBB negative regulator, intestinal stem cell
marker and tumour suppressor. Br J Cancer. 108:1765–1770. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ljuslinder I, Golovleva I, Palmqvist R,
Oberg A, Stenling R, Jonsson Y, Hedman H, Henriksson R and Malmer
B: LRIG1 expression in colorectal cancer. Acta Oncol. 46:1118–112.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Thomasson M, Wang B, Hammarsten P, Dahlman
A, Persson JL, Josefsson A, Stattin P, Granfors T, Egevad L,
Henriksson R, et al: LRIG1 and the liar paradox in prostate cancer:
A study of the expression and clinical significance of LRIG1 in
prostate cancer. Int J Cancer. 128:2843–2852. 2010. View Article : Google Scholar
|
|
8
|
Thomasson M, Hedman H, Ljungberg B and
Henriksson R: Gene expression pattern of the epidermal growth
factor receptor family and LRIG1 in renal cell carcinoma. BMC Res
Notes. 5:2162012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lindström AK, Ekman K, Stendahl U, Tot T,
Henriksson R, Hedman H and Hellberg D: LRIG1 and squamous
epithelial uterine cervical cancer: Correlation to prognosis, other
tumor markers, sex steroid hormones and smoking nternational. Int J
Glynecol Cancer. 18:312–317. 2008. View Article : Google Scholar
|
|
10
|
Guo D, Nilsson J, Haapasalo H, Raheem O,
Bergenheim T, Hedman H and Henriksson R: Perinuclear leucine-rich
repeats and immunoglobulin-like domain proteins (LRIG1-3) as
prognostic indicators in astrocytic tumors. Acta Neuropathol.
111:238–246. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mak LH and Woscholski R: Targeting PTEN
using small molecule inhibitors. Methods 77–78. 63–68. 2015.
View Article : Google Scholar
|
|
12
|
Zhang H, Sun Z and Kong Y: Expression of
PTEN, Her-2 and Glut-1 proteins in endometrial intraepithelial
neoplasia and endometrioid. Xin Jiang Yi Ke Da Xue Xue Bao.
34:142–146. 2011.
|
|
13
|
Edge SB, Byrd DR and Compton CC: AJCC
Cancer Staging Manual. 7th. New York: Springer; pp. 103–111.
2009
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee JM, Kim B, Lee SB, Jeong Y, Oh YM,
Song YJ, Jung S, Choi J, Lee S, Cheong KH, et al: Cbl-independent
degradation of Met: Ways to avoid agonism of bivalent Met-targeting
antibody. Oncogene. 33:34–43. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Goldoni S, Iozzo RA, Kay P, Campbell S,
McQuillan A, Agnew C, Zhu JX, Keene DR, Reed CC and Iozzo RV: A
soluble ectodomain of LRIG1 inhibits cancer cell growth by
attenuating basal and ligand-dependent EGFR activity. Oncogene.
26:368–381. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ledda F, Bieraugel O, Fard SS, Vilar M and
Paratcha G: Lrig1 Is an endogenous inhibitor of Ret receptor
tyrosine kinase activation, downstream signaling and biological
responses to GDNF. J Neurosci. 28:39–49. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Thomasson M, Wang B, Hammarsten P, Dahlman
A, Persson JL, Josefsson A, Stattin P, Granfors T, Egevad L,
Henriksson R, et al: LRIG1 and the liar paradox in prostate cancer:
A study of the expression and clinical significance of LRIG1 in
prostate cancer. Int J Cancer. 128:2843–2852. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jiang XF, Li H, Wang HJ, Li XM, Chen Y,
Pang ZL, Chen HM and Li HW: Research of Lrig1 in esophageal
squamous cell carcinoma. Chin J Dig. 33:123–124. 2013.
|
|
20
|
Ljuslinder I, Golovleva I, Henriksson R,
Grankvist K, Malmer B and Hedman H: Co-incidental increase in gene
copy number of ERBB2 and LRIG1 in breast cancer. Breast Cancer Res.
11:4032009. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hou G, Lu Z, Liu M, Liu H and Xue L:
Mutational analysis of the pten gene and its effects in esophageal
squamous cell carcinoma. Dig Dis Sci. 56:1315–1322. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yi W, Haapasalo H, Holmlund C, Järvelä S,
Raheem O, Bergenheim AT, Hedman H and Henriksson R: Expression of
leucine-rich repeats and immunoglobulin-like domains (Lrig)
proteins in human ependymoma relates to tumor location, who grade
and patient age. Clin Neuropathol. 28:21–27. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chappell WH, Steelman LS, Long JM, Kempf
RC, Abrams SL, Franklin RA, Bäsecke J, Stivala F, Donia M, Fagone
P, et al: Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors:
Rationale and importance to inhibiting these pathways in human
health. Oncotarget. 2:135–164. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chetram MA and Hinton CV: PTEN regulation
of ERK1/2 signaling in cancer. J Recept Signal Transduct Res.
32:190–195. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Maehama T and Dixon JE: The tumor
suppressor, PTEN/MMAC1, dephosphorylates the lipid second
messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem.
273:13375–13378. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chetram MA, Don-Salu-Hewage AS and Hinton
CV: ROS enhances CXCR4-mediated functions through inactivation of
PTEN in prostate cancer cells. Biochem Biophys Res Commun.
410:195–200. 2011. View Article : Google Scholar : PubMed/NCBI
|
